Progress in research of vaccination for patients with cancer.
10.3760/cma.j.issn.0254-6450.2018.01.021
- Author:
S Y JIA
1
;
J X LI
2
;
F C ZHU
3
,
4
Author Information
1. School of Public Health, Nanjing Medical University, Nanjing 211166, China.
2. Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
3. School of Public Health, Nanjing Medical University, Nanjing 211166, China
4. Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
- Publication Type:Journal Article
- Keywords:
Cancer;
Infection;
Vaccination
- MeSH:
China;
Humans;
Neoplasms/prevention & control*;
Research;
Vaccination/trends*
- From:
Chinese Journal of Epidemiology
2018;39(1):98-101
- CountryChina
- Language:Chinese
-
Abstract:
Due to the tumor malignancy or immunosuppressive treatment, patients with cancer in general are more susceptible to vaccine-preventable infections. The types, timing, dose of vaccination or even the immunization program for them may differ from those for the normal persons. At present, it is recommended to use inactivated vaccines for patients with cancer rather than attenuated live vaccines, Vaccinations should be avoided during immunosuppressive therapy; patients with cancer should receive double dosage of hepatitis B vaccines and two doses of inactivated influenza vaccines yearly. This paper summarizes the progress in clinical trials of vaccination for cancer patients in foreign countries, and provide reference for the development and implementation of vaccination strategy for cancer patients in China.
